search
Back to results

Pharmacokinetic Study of Levosulpiride

Primary Purpose

Dyspepsia

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Levosulpiride
Sponsored by
Wuhan Union Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Dyspepsia focused on measuring levosulpiride, pharmacokinetics, adverse effects, bioavailability

Eligibility Criteria

19 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • body mass index between19 and 24 kg/m2
  • negative for HIV and hepatitis B
  • had no clinical important findings on health tests
  • thorax radiography and ECG with no abnormalities
  • normal blood pressure values
  • heart rate

Exclusion Criteria:

  • any drug treatment within 2 weeks before starting the study
  • participation in another clinical study within the previous 3 months
  • alcoholism and smoking
  • pregnancy
  • breast-feeding
  • hypocalcemia
  • blood donation or participation in other clinical trials within 3 months before enrollment in the study
  • sitting blood pressure <80/50 mm Hg or >140/100 mm Hg
  • A ventricular rate <60 beats/min or >100 beats/min at rest

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    part 1

    part 2

    Arm Description

    12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.

    30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).

    Outcomes

    Primary Outcome Measures

    Cmax
    Peak concentration
    Area under the curve-AUC
    Area under the curve - plasma concentration
    Clearance-CL
    Clearance
    Apparent volume of distribution-V
    The apparent volume of distribution

    Secondary Outcome Measures

    Safety (adverse events)
    adverse events

    Full Information

    First Posted
    May 9, 2015
    Last Updated
    June 24, 2015
    Sponsor
    Wuhan Union Hospital, China
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02481583
    Brief Title
    Pharmacokinetic Study of Levosulpiride
    Official Title
    Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular and Intravenous Administration of Levosulpiride After Single and Multiple Doses in Fasting Healthy Chinese Volunteers
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    March 2013 (undefined)
    Primary Completion Date
    May 2013 (Actual)
    Study Completion Date
    May 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Wuhan Union Hospital, China

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The aim of this study was to characterise the pharmacokinetic properties and assess the safety of different formulations of levosulpiride in healthy Chinese volunteers.
    Detailed Description
    Levosulpiride was administered to 42 healthy male and female (1:1) subjects as tablet (orally) and injection (intramuscularly and intravenously) formulations. Blood samples were collected at regular intervals after single and multiple drug administration. The concentration of levosulpiride in plasma was determined using a validated high performance liquid chromatography-tandem mass spectrometry method. Non-compartmental analysis was performed to estimate pharmacokinetic parameters. The analysis of variance was used to test for linearity and assess the effect of gender on the pharmacokinetic properties of the study drug. Adverse effects were monitored using investigators' questionnaires and subjects' spontaneous reports, vital sign measurements, hematology, clinical chemistry, and electrocardiogram.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Dyspepsia
    Keywords
    levosulpiride, pharmacokinetics, adverse effects, bioavailability

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    42 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    part 1
    Arm Type
    Experimental
    Arm Description
    12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
    Arm Title
    part 2
    Arm Type
    Experimental
    Arm Description
    30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
    Intervention Type
    Drug
    Intervention Name(s)
    Levosulpiride
    Intervention Description
    different formulations of levosulpiride
    Primary Outcome Measure Information:
    Title
    Cmax
    Description
    Peak concentration
    Time Frame
    two days
    Title
    Area under the curve-AUC
    Description
    Area under the curve - plasma concentration
    Time Frame
    two days
    Title
    Clearance-CL
    Description
    Clearance
    Time Frame
    two days
    Title
    Apparent volume of distribution-V
    Description
    The apparent volume of distribution
    Time Frame
    two days
    Secondary Outcome Measure Information:
    Title
    Safety (adverse events)
    Description
    adverse events
    Time Frame
    one month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    19 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: body mass index between19 and 24 kg/m2 negative for HIV and hepatitis B had no clinical important findings on health tests thorax radiography and ECG with no abnormalities normal blood pressure values heart rate Exclusion Criteria: any drug treatment within 2 weeks before starting the study participation in another clinical study within the previous 3 months alcoholism and smoking pregnancy breast-feeding hypocalcemia blood donation or participation in other clinical trials within 3 months before enrollment in the study sitting blood pressure <80/50 mm Hg or >140/100 mm Hg A ventricular rate <60 beats/min or >100 beats/min at rest
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Weiyong Li
    Organizational Affiliation
    HUST/Union Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    26404395
    Citation
    Xu M, Zhou Y, Ni Y, He X, Li H, Sattar H, Chen H, Li W. Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. Clin Ther. 2015 Nov 1;37(11):2458-67. doi: 10.1016/j.clinthera.2015.08.024. Epub 2015 Sep 26.
    Results Reference
    derived

    Learn more about this trial

    Pharmacokinetic Study of Levosulpiride

    We'll reach out to this number within 24 hrs